Zymeworks Announces Participation in Upcoming Investor Conferences
March 27, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
March 06, 2024 16:09 ET
|
Zymeworks Inc.
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
March 05, 2024 16:30 ET
|
Zymeworks Inc.
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...
Zymeworks Announces Participation in Upcoming Investor Conferences
February 27, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
February 14, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
February 08, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
January 31, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
January 04, 2024 06:15 ET
|
Zymeworks Inc.
Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 (unaudited)Expected cash runway, including proceeds...
Zymeworks Announces Additional Leadership Appointments
January 04, 2024 06:00 ET
|
Zymeworks Inc.
Dr. Jeffrey Smith named Executive Vice President and Chief Medical OfficerDr. John Fann promoted to Senior VP, Process SciencesSeven new Vice Presidents appointed, underscoring commitment to...
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
December 26, 2023 08:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today...